fluorouracil has been researched along with CACH Syndrome in 23 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome." | 8.31 | Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report. ( Hemachudha, P; Phuenpathom, W; Pongpitakmetha, T; Rattanawong, W, 2023) |
| "A 55-year-old woman with a 3-year and 4-month history of liver metastasis from breast cancer underwent chemotherapy with capecitabine and cyclophosphamide for following 10-months." | 7.78 | [Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer]. ( Ishikawa, T; Tukamoto, Y; Yasaki, S; Yoshii, F; Yuasa, N, 2012) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-fluorouracil within tumors, resulting in enhanced concentrations of 5-fluorouracil in tumor tissue." | 6.82 | Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature. ( Abu-Shahin, FI; Brown, EN; Liu, L, 2022) |
| "Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome." | 4.31 | Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report. ( Hemachudha, P; Phuenpathom, W; Pongpitakmetha, T; Rattanawong, W, 2023) |
| "5 T) was performed in 187 CMF (cyclophosphamide, methotrexate, and 5-flourouracil) chemotherapy-exposed breast cancer survivors, mean age 64." | 3.80 | Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. ( Boogerd, W; Breteler, MM; de Groot, M; de Ruiter, MB; Koppelmans, V; Niessen, WJ; Schagen, SB; Seynaeve, C; Vernooij, MW, 2014) |
| "A 55-year-old woman with a 3-year and 4-month history of liver metastasis from breast cancer underwent chemotherapy with capecitabine and cyclophosphamide for following 10-months." | 3.78 | [Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer]. ( Ishikawa, T; Tukamoto, Y; Yasaki, S; Yoshii, F; Yuasa, N, 2012) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-fluorouracil within tumors, resulting in enhanced concentrations of 5-fluorouracil in tumor tissue." | 2.82 | Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature. ( Abu-Shahin, FI; Brown, EN; Liu, L, 2022) |
| "The patient was diagnosed with acute leukoencephalopathy, and the capecitabine treatment was discontinued." | 2.50 | [Early diagnosis of capecitabine-induced acute leukoencephalopathy by using diffusion-weighted MRI]. ( Ban, T; Ikegaya, Y; Isogai, N; Kawachi, J; Miyake, K; Ogino, H; Shimoyama, R; Watanabe, K, 2014) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-FU within tumors, resulting in enhanced concentrations of 5-FU in tumor tissue." | 2.49 | Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. ( Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y, 2013) |
| "The capecitabine treatment was terminated, and methylprednisolone treatment was administered and plasmapheresis procedure was carried out." | 1.91 | Capecitabine-related neurotoxicity presenting with agraphia. ( Bayram, E; Bicakci, S; Demir, T; Iscan, D; Tolay, R, 2023) |
| "Acute toxic leukoencephalopathy (ATL) is a rare complication of cancer treatment, with symptoms varying from mild cognitive impairment to coma." | 1.91 | FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy. ( Karaçin, C; Öztaş, A; Sertesen, E; Yoloğlu, Z, 2023) |
| "The presenting symptoms of 5-FU-induced leukoencephalopathy are often confusing and pose a diagnostic dilemma in routine clinical practice." | 1.72 | Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series. ( Georgy, JT; Joel, A; John, AO; Jose, N; Ram, TS; Ramireddy, J; Selvakumar, RJ; Singh, A, 2022) |
| "Toxic leukoencephalopathy predominantly affect white matter of the brain parenchyma." | 1.56 | Toxic Leukoencephalopathy: An unusual Presentation by 5-Fluorouracil Infusion. ( Meena, VK; Narayan, S; Pareek, P; Soni, S, 2020) |
| "Acute toxic leukoencephalopathy (ATL) is a rare adverse effect of 5-Fluorouracil (5-FU) chemotherapeutic agent." | 1.40 | 5-FU induced acute toxic leukoencephalopathy: early recognition and reversibility on DWI-MRI. ( Azeemuddin, M; Maheen Anwar, SS; Mubarak, F; Sajjad, Z, 2014) |
| "A diagnosis of acute leukoencephalopathy was reached based on these findings." | 1.37 | Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI. ( Akitake, R; Chiba, T; Ezoe, Y; Horimatsu, T; Miyamoto, S; Muto, M; Nakamura, F, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L | 1 |
| Brown, EN | 1 |
| Abu-Shahin, FI | 1 |
| Jose, N | 1 |
| Joel, A | 1 |
| Selvakumar, RJ | 1 |
| Ramireddy, J | 1 |
| John, AO | 1 |
| Georgy, JT | 1 |
| Singh, A | 1 |
| Ram, TS | 1 |
| Iscan, D | 1 |
| Tolay, R | 1 |
| Bayram, E | 1 |
| Demir, T | 1 |
| Bicakci, S | 1 |
| Hemachudha, P | 1 |
| Rattanawong, W | 1 |
| Pongpitakmetha, T | 1 |
| Phuenpathom, W | 1 |
| Sertesen, E | 1 |
| Öztaş, A | 1 |
| Karaçin, C | 1 |
| Yoloğlu, Z | 1 |
| Meena, VK | 1 |
| Pareek, P | 1 |
| Narayan, S | 1 |
| Soni, S | 1 |
| Perrain, V | 1 |
| Bihan, K | 1 |
| Bompaire, F | 1 |
| Houillier, C | 1 |
| Jomier, F | 1 |
| Leclercq, D | 1 |
| Combret, S | 1 |
| Mahé, J | 1 |
| Ricard, D | 1 |
| Berzero, G | 1 |
| Psimaras, D | 1 |
| Acharya, G | 1 |
| Cruz Carreras, MT | 1 |
| Rice, TW | 1 |
| Fukumoto, T | 1 |
| Katada, F | 1 |
| Sato, S | 1 |
| Shibayama, H | 1 |
| Murayama, S | 1 |
| Fukutake, T | 1 |
| Lowry, LE | 1 |
| Fenderson, JL | 1 |
| Baur, RA | 1 |
| Kinno, R | 1 |
| Kii, Y | 1 |
| Uchiyama, M | 1 |
| Owan, Y | 1 |
| Yamazaki, T | 1 |
| Fukui, T | 1 |
| Mehta, S | 1 |
| Singh, G | 1 |
| Paul, BS | 1 |
| Endo, A | 1 |
| Yoshida, Y | 1 |
| Nakashima, R | 1 |
| Takahashi, N | 1 |
| Tanabe, K | 1 |
| Maheen Anwar, SS | 1 |
| Mubarak, F | 1 |
| Sajjad, Z | 1 |
| Azeemuddin, M | 1 |
| Goto, N | 1 |
| Mimura, J | 1 |
| Miyamoto, S | 2 |
| Shimoyama, R | 1 |
| Ban, T | 1 |
| Miyake, K | 1 |
| Isogai, N | 1 |
| Ikegaya, Y | 1 |
| Kawachi, J | 1 |
| Ogino, H | 1 |
| Watanabe, K | 1 |
| Sierra, S | 1 |
| Luquin, N | 1 |
| Carrato, C | 1 |
| Akitake, R | 1 |
| Nakamura, F | 1 |
| Horimatsu, T | 1 |
| Ezoe, Y | 1 |
| Muto, M | 1 |
| Chiba, T | 1 |
| Li, J | 1 |
| Lee, JJ | 1 |
| Chu, E | 1 |
| Baehring, JM | 1 |
| Bang, M | 1 |
| Weon, YC | 1 |
| Yoo, HJ | 1 |
| Kwon, JH | 1 |
| Yasaki, S | 1 |
| Tukamoto, Y | 1 |
| Yuasa, N | 1 |
| Ishikawa, T | 1 |
| Yoshii, F | 1 |
| Koppelmans, V | 1 |
| de Groot, M | 1 |
| de Ruiter, MB | 1 |
| Boogerd, W | 1 |
| Seynaeve, C | 1 |
| Vernooij, MW | 1 |
| Niessen, WJ | 1 |
| Schagen, SB | 1 |
| Breteler, MM | 1 |
4 reviews available for fluorouracil and CACH Syndrome
| Article | Year |
|---|---|
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, | 2022 |
Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Humans; Leukoencephalopathies; R | 2021 |
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasm | 2013 |
[Early diagnosis of capecitabine-induced acute leukoencephalopathy by using diffusion-weighted MRI].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diff | 2014 |
19 other studies available for fluorouracil and CACH Syndrome
| Article | Year |
|---|---|
Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leukoencephalopathies; Neoplasms | 2022 |
Capecitabine-related neurotoxicity presenting with agraphia.
Topics: Adult; Agraphia; Capecitabine; Dysarthria; Fluorouracil; Humans; Leukoencephalopathies; Male | 2023 |
Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report.
Topics: Aged; Colonic Neoplasms; Fluorouracil; Humans; Leukoencephalopathies; Male; Neuroleptic Malignant Sy | 2023 |
FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy.
Topics: Bevacizumab; Diffusion Magnetic Resonance Imaging; Fluorouracil; Humans; Leukoencephalopathies; Male | 2023 |
Toxic Leukoencephalopathy: An unusual Presentation by 5-Fluorouracil Infusion.
Topics: Female; Fluorouracil; Humans; Leukoencephalopathies; Middle Aged | 2020 |
5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Corpus Callosum; Fluorouracil; Humans; | 2017 |
[A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole].
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Drug Therapy, Combinatio | 2018 |
Not All That Slurs Is Stroke: A Case of Chemotherapy-Induced Leukoencephalopathy.
Topics: Aged; Fluorouracil; Humans; Leukoencephalopathies; Male; Speech Disorders | 2019 |
5-fluorouracil-induced leukoencephalopathy with acute stroke-like presentation fulfilling criteria for recombinant tissue plasminogen activator therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fibrinolytic Agents; Fluorouracil; Humans; Infusions | 2014 |
Teaching NeuroImages: 5-FU-induced acute leukoencephalopathy.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; | 2013 |
5-FU induced acute toxic leukoencephalopathy: early recognition and reversibility on DWI-MRI.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Diffusion Magnetic Resonance Imaging; Esophag | 2014 |
Gastrointestinal: bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
[Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antihypertensive Agents; A | 2014 |
Lethal leukoencephalopathy secondary to Tegafur, a 5-fluorouracil prodrug.
Topics: Aged; Antimetabolites, Antineoplastic; Fatal Outcome; Fluorouracil; Humans; Leukoencephalopathies; M | 2015 |
Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Brain; Diffusion Magnetic Resonance Imaging; Early D | 2011 |
Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dihydropy | 2012 |
MR imaging in the early stage of 5-fluorouracil-induced leukoencephalopathy: DWI, MR perfusion, and MR spectroscopy.
Topics: Adult; Brain; Diffusion Magnetic Resonance Imaging; Female; Fluorouracil; Humans; Image Processing, | 2012 |
[Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2012 |
Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Breast Neoplasms | 2014 |